🧪 Unregulated Additives in Compounded GLP-1 Medications
The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which often include vitamins, amino acids, and other compounds, are marketed under the pretense of enhancing effectiveness, minimizing side effects, or offering a personalized solution for patients. However, the document highlights […]
Novo Nordisk loses Wegovy patent fight against generics maker Viatris
Novo Nordisk faced a setback in its bid to stave off Wegovy generics after a federal court held that Viatris’ proposed product doesn’t infringe a GLP-1-related patent. The ruling deals a …
Ozempic Might Be the Future of Addiction Treatment
GLP-1 drugs, originally meant to manage diabetes and obesity, could also help people kick hardcore addictions to alcohol, opioids, and even gambling. Reported by STAT News, with a hat tip to Futurism’s Noor Al-Sibai, at Caron Treatment Center, a high-end rehab facility in Pennsylvania, doctors are experimenting with GLP-1 meds like Ozempic and Wegovy to […]
China GLP-1 drug study suggests pound rebound likely after treatment
A Chinese analysis of prescription anti-obesity medications has added to evidence that people who use popular GLP-1 drugs such as Ozempic to shed pounds face the prospect of “significant” weight rebound once they stop using them – challenges similar to those presented by more traditional slimming strategies. Patients saw “significant weight” return eight weeks after […]
World-first obesity pill reprograms fat cells to burn calories with zero effort
The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial. Continue Reading Category: Obesity, Illnesses and conditions, Body & Mind Tags: Obesity, GLP-1 receptor agonists, Weight Loss, Brown fat, Beige fat, Body fat, Fat cells, Diabetes
Tirzepatide Tops TRT for Men With Hypogonadism and Obesity
Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile dysfunction than those treated with testosterone. Medscape Medical News
AstraZeneca Commits $50B More to U.S. Manufacturing, R&D Projects
AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of manufacturing and R&D projects planned over the next five years. The cornerstone of AstraZeneca’s latest $50 billion commitment, on top of $3.5 billion announced last November, will be the largest-ever facility the company has ever built to […]
Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists
Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.
GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes
GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.